echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junshi Biologics submits Claudin 18.2 monoclonal antibody clinical application

    Junshi Biologics submits Claudin 18.2 monoclonal antibody clinical application

    • Last Update: 2021-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 10, Junshi Bio announced that the submitted clinical trial application for JS012 injection was accepted by the Food and Drug Administration for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer


    The active ingredient of JS012 injection is a recombinant humanized anti-Claudin 18.


    Claudin protein is an important molecule that constitutes tight junctions of cells, and 27 members of this protein family have been discovered


    Up to now, no similar target product at home and abroad has been approved for listing


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.